September 2021
A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026)

Cranston RD, Brown E, Bauermeister J, Dunne EF, Hoesley C, Ho K, Johnson S, Lucas J, Dominguez-Islas C, Gundacker H, Peda M, Jacobson CE, Kramzer L, Singh D, Dezzutti CS, Ayudhya RPKN, Brand RM, Wang... More »
August 2021
A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study)

McGowan IM, Chawki S, Hendrix CW, Anton PA, Marzinke MA, Brand RM, Engstrom JC, Rohan LC, Abebe KZ, Richardson-Harman N, Siegel A, Rineheart A, Steytler J, Stall R, Spiegel H, Chen B, Achilles SL,... More »
July 15 2021
Research on dapivirine ring use among adolescent girls and young women presented at IAS 2021

July 15, 2021—Interim results from REACH, an open-label study of IPM’s monthly dapivirine ring as well as of daily oral PrEP, are being presented at the 11th IAS Conference on HIV Science (IAS 2021... More »
July 2021
Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrel

Bashi YHD, Murphy DJ, McCoy CF, Boyd P, Brown L, Kihara M, Martin F, McMullen N, Kleinbeck K, Dangi B, Spence P, Hansraj B, Devlin B, Malcolm RK. Int J Pharm X. 2021 Jul; 3:100091. doi.org/10.1016/j.... More »
June 16 2021
IPM Appoints to its Board of Directors Two Leading Advocates at the Forefront of Women’s Sexual and Reproductive Health and Rights and HIV Prevention

SILVER SPRING, Md. (June 16, 2021)—The nonprofit International Partnership for Microbicides (IPM) today announced the appointments of Dr. Tlaleng Mofokeng and Ms. Lillian Mworeko to its Board of... More »